Last reviewed · How we verify

Licorice Root

Cairo University · FDA-approved active Small molecule Quality 2/100

Licorice Root, marketed by Cairo University, holds a unique position in the natural remedies segment, leveraging its long-standing traditional use. The key composition patent, set to expire in 2028, provides a significant barrier to entry for potential competitors. However, the lack of a defined primary indication and revenue data poses a strategic risk, potentially limiting its market expansion and investment appeal.

At a glance

Generic nameLicorice Root
Also known asGlycyrrhiza Glabra
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: